COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,861 Articles (22,568 medRxiv, 8,293 bioRxiv)

Most recent first Previous |  Page 2099: Articles 20981-20990  | Next

Emergency Response for Evaluating SARS-CoV-2 Immune Status, Seroprevalence and Convalescent Plasma in Argentina
Ojeda, D., Gonzalez Lopez Ledesma, M. M., Palleres, H., Costa Navarro, G., Sanchez, L., Perazzi, B., Villordo, S., Alvarez, D., BioBanco Working Group, , Echavarria, M., Oguntuyo, K. Y., Stevens, C., Lee, B., Carradori, J., Caramelo, J., Yanovsky, M., Gamarnik, A.
10.1101/2020.10.21.20216960 — Posted: 2020-10-23
Exposome changes in primary school children following the wide population non-pharmacological interventions implemented due to COVID-19 in Cyprus: a national survey
Konstantinou, C., Andrianou, X. D., Constantinou, A., Perikkou, A., Markidou, E., Christophi, C. A., Makris, K. C.
10.1101/2020.10.21.20216978 — Posted: 2020-10-23
Twitter Engagement of U.S. Psychiatry Residency Programs with Black Lives Matter and Coronavirus Disease 2019 (COVID-19)
El-Gabalawy, O., Kim, C., Chen, A., Kamal, S.
10.1101/2020.10.20.20215723 — Posted: 2020-10-23
SARS-CoV-2 Nucleocapsid protein attenuates stress granule formation and alters gene expression via direct interaction with host mRNAs
Nabeel-Shah, S., Lee, H., Ahmed, N., Marcon, E., Farhangmehr, S., Pu, S., Burke, G. L., Ashraf, K., Wei, H., Zhong, G., Tang, H., Yang, J., Blencowe, B., Zhang, Z., Greenblatt, J. F.
10.1101/2020.10.23.342113 — Posted: 2020-10-23
Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects
Nguyen, H. T., Zhang, S., Wang, Q., Anang, S., Wang, J., Ding, H., Kappes, J. C., Sodroski, J. G.
10.1101/2020.10.22.351569 — Posted: 2020-10-23
Transferrin receptor is another receptor for SARS-CoV-2 entry
Tang, X., Yang, M., Duan, Z., Liao, Z., Liu, L., Cheng, R., Fang, M., Wang, G., Liu, H., Xu, J., Kamau, P. M., Zhang, Z., Yang, L., Zhao, X., Peng, X., Lai, R.
10.1101/2020.10.23.350348 — Posted: 2020-10-23
Direct visualization of native infectious SARS-CoV-2 ant its inactivation forms using high resolution Atomic Force Microscopy
Lyonnais, S., Henaut, M., Neyret, A., Merida, P., Gros, N., Chable-Bessia, C., Muriaux, D.
10.1101/2020.10.23.351916 — Posted: 2020-10-23
Potential Achilles heels of SARS-CoV-2 displayed by the base order-dependent component of RNA folding energy
Zhang, C., Forsdyke, D. R.
10.1101/2020.10.22.343673 — Posted: 2020-10-23 Discussion: Onsite
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine
Jangra, S., De Vrieze, J., Choi, A., Rathnasinghe, R., Laghlali, G., Uvyn, A., Van Herck, S., Nuhn, L., Deswarte, K., Zhong, Z., Sanders, N., Lienenklaus, S., David, S., Strohmeier, S., Amanat, F., Krammer, F., Hammad, H., Lambrecht, B. N., Coughlan, L., Garcia-Sastre, A., De Geest, B. G., Schotsaert, M.
10.1101/2020.10.23.344085 — Posted: 2020-10-23
mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents
Rauch, S., Roth, N., Schwendt, K., Fotin-Mleczek, M., Mueller, S. O., Petsch, B.
10.1101/2020.10.23.351775 — Posted: 2020-10-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).